For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ MGF
Illustration for MGF

THE PEPSRADAR ENCYCLOPEDIA

MGF

Muscle-cell signaling and replication findings

Research topics · Sources checked 2026-10-04

Read the studies ↓

MGF · KEY FACTS

Content updated · how dates work

What is MGF?

MGF can refer to an IGF-1 splice-product context or a synthetic terminal E-peptide. A primary replication study found no apparent effect of the tested MGF peptides on muscle-cell proliferation or differentiation.

Video overview · 3:22

PEG-MGF (Mechano Growth Factor): Does It Build Muscle? What the Research Shows

Where mechano growth factor comes from, the cell studies behind the muscle claim, the two-company replication that found no effect, why PEG-MGF itself has never been studied, and its FDA, compounding and anti-doping status.

Narrated with an AI voice from this profile's sources; education only, no dosing.

Read the transcript

PEG-MGF is sold online as a muscle-building peptide, and the FDA's compounding panel is due to review it by early 2027. The story behind it starts with a real discovery in stretched muscle. But PEG-MGF itself has never been studied. Here's what's actually known.

In 1996, a London team led by Geoffrey Goldspink found an unusual version of the growth factor IGF-1 in stretched muscle. It was later named mechano growth factor. What's sold online is a short lab-made piece of its tail, about twenty-four amino acids. PEG-MGF is that piece with polyethylene glycol attached, meant to make it last longer.

Here's the idea. Loading a muscle switches on mechano growth factor, which was proposed to wake up muscle stem cells, called satellite cells, so they multiply and help repair. In older rats, muscle made much less of it. Whether a vial of the lab-made piece does any of this in a person has never been tested.

In 2002, the original team reported that the tail piece made muscle cells multiply in a dish. A 2011 study saw longer growth in muscle cells from young donors, but not from older ones. Then, in 2014, scientists at two drug companies tried to repeat the work. The peptide had no effect on mouse or human muscle cells, while ordinary IGF-1 worked in the same tests.

Outside muscle, modified versions of the peptide helped heart function after heart attacks in mice, and helped bone and cartilage repair in rabbits. But those studies used other forms of the peptide, some stabilized differently or released from a scaffold. We found no published study of PEG-MGF itself, in cells, animals or people.

In people, nobody has been given MGF or PEG-MGF in a published or registered trial. The one well-known human study only measured the body's own MGF: after heavy leg exercise, it rose in eight young men, but not in seven older men.

PEG-MGF is not FDA approved. The FDA warns it may carry a significant risk of immune reactions, notes impurity concerns, and says it has found no human exposure data. It's on the agenda for the FDA's next compounding advisory meeting. Anti-doping labs have found mislabeled MGF products, and the World Anti-Doping Agency bans mechano growth factors at all times.

Does PEG-MGF build muscle in people? Unproven: no human trial has given it. Does MGF activate muscle stem cells? Mixed: the original lab says yes, a two-company replication found nothing. Does PEG-MGF work like MGF, only longer? Unknown: it has never been studied. And is it allowed in sport? No.

The bottom line: mechano growth factor is a real form of IGF-1 that muscle makes when it's loaded. But the muscle-building claim rests on cell studies that a careful replication couldn't confirm, PEG-MGF has never been studied, and it isn't approved. For every study and source, see the PEG-MGF profile on PepsRadar dot com.

Biological role or research focus

Muscle-cell signaling and replication findings.

Negative replication challenges broad muscle-regeneration claims. It does not prove that every splice product or future preparation lacks activity in all settings.

Role reference: Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. · 2014 ↗

Names you may encounter

Mechano-growth factor · MGF E-peptide

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
IGF-1 splice-product / E-peptide research label
Research focus
Muscle-cell signaling and replication findings
Featured evidence
Cell study with negative replication findings
Source check
October 4, 2026

Source: Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. · 2014 ↗

Quick answers

Is MGF FDA approved?
No. No FDA-approved drug contains MGF. FDA lists it in 503A category 3: nominated for compounding without enough supporting information. Source ↗
Is MGF safe?
Unapproved IGF-1 splice fragment with no published human safety studies. A replication study found no clear effect on muscle cells, and risks in people are unknown. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
Is MGF banned in sport?
Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.3 Growth factors and growth factor modulators). Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Cell experiments
StudyTypePopulation / model
MGF peptide replication in muscle cells (2014)Cell study with negative replication findingsC2C12 cells, primary human muscle myoblasts, and primary mouse muscle stem cells.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Cell study with negative replication findings · 2014

MGF peptide replication in muscle cells

What did this publication test, and what did it find?

Population / model
C2C12 cells, primary human muscle myoblasts, and primary mouse muscle stem cells.
Study design
Laboratory attempts to reproduce proposed proliferation, differentiation, and signaling effects using MGF peptides and IGF-1-related controls.
Main finding
MGF did not increase proliferation or inhibit differentiation in the tested systems. IGF-1 and full-length IGF-1Eb produced proliferative responses; tested MGF peptides also failed to demonstrate the proposed signaling response.
Limits & context
Negative replication challenges broad muscle-regeneration claims. It does not prove that every splice product or future preparation lacks activity in all settings.

Source: Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. · 2014 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

No study naming MGF as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction. ↗
Heart, lung & circulation · 2008 Feb · Comparative Study, Journal Article

African swine fever virus MGF_110-3L and MGF_110-4L signal TLR2-mediated lethal inflammation. ↗
Protein & cell · 2026 Jul 14 · Journal Article

Growth factors and muscle ageing. ↗
Experimental gerontology · 2004 Oct · Journal Article, Research Support, Non-U.S. Gov't, Review

Mangiferin: A natural neuroprotective polyphenol with anti-inflammatory and anti-oxidant properties for depression. ↗
Progress in neuro-psychopharmacology & biological psychiatry · 2025 Jun 20 · Journal Article, Review, Research Support, Non-U.S. Gov't

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Unapproved IGF-1 splice fragment with no published human safety studies. A replication study found no clear effect on muscle cells, and risks in people are unknown.

Human safety data: None

No published human safety studies were found. Evidence comes from cell and animal experiments, and a careful replication study found tested MGF peptides had no apparent effect on muscle cells. Safety of products sold as MGF is unknown.

Unassessed: no human safety data

It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.

Who should not use it

There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.

Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: MGF peptide has no apparent effect on myoblasts or muscle stem cells (2014) ↗

Safety & what remains unknown

Cell experiments do not establish systemic safety or a useful human muscle-recovery intervention.

Source: Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. · 2014 ↗

Evidence boundaries

Negative replication challenges broad muscle-regeneration claims. It does not prove that every splice product or future preparation lacks activity in all settings.

Source: Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. · 2014 ↗

Regulatory status

U.S. FDA approval
Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source
FDA compounding (503A bulk list)
Category 3 (nominated without enough support)
Listed in 503A category 3 ("Mechano growth factor (MGF)", nominated without adequate support). source
World Anti-Doping Agency (2026)
Prohibited, named on the list · S2.3 Growth factors and growth factor modulators
Named explicitly ("Mechano growth factors (MGFs)"). source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Research context & identity

This profile covers unpegylated MGF peptide research. PEG-MGF is a different conjugate whose sequence, polymer, and attachment must be specified.

Source: Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. · 2014 ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Seller lab-report checks and prices are available to members. Sign up free

Biology & proposed mechanism

The study separated a synthetic terminal fragment from mature IGF-1 and full-length IGF-1Eb. A response to the full protein cannot be attributed automatically to the isolated fragment.

Source: Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. · 2014 ↗

Questions worth asking

  • Is MGF peptide evidence interchangeable with PEG-MGF or IGF-1 evidence?
  • What material, population, and route were actually studied?
  • Negative replication challenges broad muscle-regeneration claims. It does not prove that every splice product or future preparation lacks activity in all settings.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Video & podcast discussions: members library

Frequently asked questions

Is MGF peptide evidence interchangeable with PEG-MGF or IGF-1 evidence?

No. A terminal fragment, a full-length growth factor, and a PEG conjugate are different preparations. The negative fragment findings should remain visible.

Source: Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. · 2014 ↗

Does the publication verify a supplier’s product?

No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.

Source: Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. · 2014 ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections